[Association between DRD2 gene polymorphisms and the dosage used on methadone maintenance treatment program]

Area of Science:

• Pharmacogenetics
• Neuroscience
• Addiction Medicine

Background:

• Methadone maintenance treatment (MMT) is a cornerstone for opioid use disorder management.
• Individual variability in methadone dosage requirements necessitates understanding genetic influences.
• Dopamine receptor D2 (DRD2) gene polymorphisms are implicated in drug response and addiction.

Purpose of the Study:

• To investigate the association between DRD2 single nucleotide polymorphisms (SNPs) (rs1800497, rs6275, rs1799978) and methadone dosage in MMT patients.
• To explore potential genetic markers for optimizing methadone treatment regimens.

Main Methods:

• A case-control study involving 257 MMT patients, categorized into low-dose and high-dose groups.
• Genotyping of DRD2 SNPs (rs1800497, rs6275, rs1799978) using established methods.
• Statistical analysis to compare SNP distributions and their correlation with methadone dosage.

Main Results:

• A significant association was found between the DRD2 rs6275 polymorphism and methadone dosage.
• Patients with TC genotype at rs6275 and those carrying the C allele required significantly lower methadone doses.
• No significant associations were observed for DRD2 SNPs rs1800497 and rs1799978 with methadone dosage.

Conclusions:

• The DRD2 rs6275 polymorphism is a potential predictor of methadone dosage requirements in MMT.
• These findings suggest that DRD2 rs6275 genotype may inform personalized methadone dosing strategies.
• Further research is warranted to validate these findings and explore clinical utility.